MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03859nas a22003257a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20210315161836.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m|||||r|||| 00| 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
ta |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
171219t2008 sp ||||| |||| 00| 0 spa | |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0025-7753 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
Salus Infirmorum |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Estudio piloto sin grupo control del tratamiento con magnesio y vitamina B6 del síndrome de Gilles de la Tourette en niños = |
| Remainder of title |
An open study evaluating the efficacy and security of magnesium and vitamin B6 as a treatment of Tourette syndrome in children / |
| Statement of responsibility, etc. |
Rafael García-Lópeza , Julio Romero-Gonzálezb, Emilio Perea-Millac , César Ruiz-Garcíad, Francisco Rivas-Ruizc y Mariano de las Mulas Béjar |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Este artículo se encuentra disponible en su edición impresa. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliografía: p.691 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
FUNDAMENTO Y OBJETIVO: Estudiar la efectividad y seguridad de soluciones orales de magnesio y vitamina B6 para disminuir los síntomas durante las exacerbaciones clínicas en niños de entre 7 y 14 años con síndrome de Gilles de la Tourette (SGT). Determinar la mejoría en la puntuación y su desviación estándar para estimar el tamaño muestral de futuros ensayos con grupo control.<br/>PACIENTES Y MÉTODO: El tratamiento estudiado se administró a niños diagnosticados de SGT de acuerdo con el Manual Diagnóstico y Estadística de los Trastornos Mentales, cuarta edición, durante una exacerbación clínica. La clínica se cuantificó mediante la Yale Global Tics Severity Scale (YGTSS) a los 0, 15, 30, 60 y 90 días de tratamiento.<br/>RESULTADOS: La puntuación de los tics pasó de 26,7 (inicio) a 12,9 (a los 90 días de tratamiento) y la puntuación total de la YGTSS pasó de 58,1 a 18,8. Estos resultados fueron estadísticamente significativos. Con respecto a la aplicación o no de<br/>tratamiento convencional, no observamos diferencias significativas en los resultados obtenidos. No se registraron efectos secundarios.<br/>CONCLUSIONES: El tratamiento analizado es seguro y efectivo para reducir los síntomas del SGT en niños. Es necesario realizar estudios con un grupo control y diferentes dosis de fármacos para confirmar estos resultados. |
| 520 8# - SUMMARY, ETC. |
|---|
| Summary, etc. |
BACKGROUND AND OBJECTIVE: We intended to ascertain the effectiveness and safety of oral solutions of magnesium and vitamin B6 in alleviating the symptoms emerged during clinical exacerbations in children aged 7-14 years suffering from Tourette syndrome (TS). We also aimed to determine the mean and the standard deviation of such an improvement in order to estimate sample sizes in future assays with a control group.<br/>PATIENTS AND METHOD: The treatment under investigation was administered to children diagnosed with TS, in accordance with Diagnostic and Statistical Manual of Mental Disorders, fourth edition -IV, under conditions of clinical exacerbation. The effects<br/>were scored on the Yale Global Tics Severity Scale (YGTSS) at 0, 15, 30, 60 and 90 days.<br/>RESULTS: The total tics score decreased from 26.7 (t0) to 12.9 (t4) and the total effect on the YGTSS was a reduction from 58.1 to 18.8. Both results were statistically significant. With respect to the application of conventional treatment or otherwise, no significant differences were observed. No side effects were seen.<br/>CONCLUSIONS: The treatment assayed is safe and effective in reducing the harmful effects of TS in children. Further studies are needed, with a control group, and evaluation of different doses of the drugs |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Síndrome de Gilles de la Tourette |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Tics |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Tratamiento |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Magnesio |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Vitamina B |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Tourette syndrome |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Tics |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Therapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Magnesium |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Vitamin B |
| 773 ## - HOST ITEM ENTRY |
|---|
| Related parts |
-- 2008, v. 131, n. 18, p. 689-691 |
| Title |
Medicina clínica |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Universal Decimal Classification |
| Koha item type |
Artículo de revista |
